Navigation Links
BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite
Date:8/21/2014

cally significant improvement in the post-hoc composite responder analysis, as measured by combined investigator and patient GAIS scores, with p-values of 0.021 and 0.004, respectively, versus placebo.
  • While the trial was not designed to quantify changes in cellulite dimple measurements, 3-D photography was utilized to enable visualization of treatment effects. View photos here.
  • CCH was well-tolerated by all dose groups with most adverse events being mild-to-moderate and primarily limited to the local injection area; 86 percent of all related adverse events resolved within 21 days and there was only one serious adverse event in the trial, determined to be unrelated to the treatment drug.
  • About Cellulite

    Edematous fibrosclerotic panniculopathy, commonly known as cellulite, describes a condition in which lobules of subcutaneous adipose tissue extend into the dermal layer. Cellulite can involve the loss of elasticity or shrinking of collagen cords, called septae, that attach the skin to lower layers of muscle. When fat in cellulite prone areas swells and expands, the septae tether the skin, which causes surface dimpling characteristic of cellulite. These changes can visibly affect the shape of the epidermis and resemble an orange peel-like dimpling of the skin.

    About BioSpecifics Technologies Corp.

    BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium). Auxilium has the following partnerships outside the U
    '/>"/>

    SOURCE BioSpecifics Technologies Corp.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
    2. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
    3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
    4. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
    5. BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
    6. BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    7. BioSpecifics Technologies Corp. Announces Partnership between Auxilium and Swedish Orphan Biovitrum AB for XIAPEX in Eurasia and Africa
    8. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2013 Financial Results on Tuesday, November 12, 2013
    9. BioSpecifics Technologies Corp. Announces Top-line Data from Phase 2 Trial of CCH for Canine Lipoma
    10. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
    11. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ... new report "Biomarkers - Technologies, Markets and ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
    (Date:3/4/2015)... CA (PRWEB) March 04, 2015 ... leader in Personalized Medicine, is excited to announce ... Genetic Testing to Optimize the Management of Pain”. ... available at Medscape.com for the next year. The ... professionals how to recognize inadequate pain treatments, integrate ...
    (Date:3/4/2015)... Follow us on LinkedIn - ... growing technologies in the life sciences industry. Growing global ... growth in nucleic acid detection technologies like qPCR and ... will continue to benefit the qPCR and dPCR instruments ... pharma, biotech, food & beverage to animal feed, will ...
    (Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
    Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
    ... SHANGHAI, July 15 /PRNewswire-Asia-FirstCall/ -- ... a leading Chinese firm,specializing in the manufacture, research, development, ... results for,the fourth quarter and fiscal year ended March ... 2009 Highlights, -- Net sales increased ...
    ... Mass., July 14 The Huffington Post -- ,The ... with astronomer Bob Berman) " Biocentrism." The article by ... universe. The Huffington Post is ranked the most powerful ... over 20 million thought-leaders, and has featured celebrity contributors from politics ...
    ... EnVivo Pharmaceuticals today announced at the Alzheimer,s Association 2009 ... deficits observed in an Alzheimer,s disease transgenic animal model after ... data was disclosed as part of the preclinical characterization of ... , EVP-0962 is a proprietary small molecule that ...
    Cached Biology Technology:China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13New Scientific Worldview 'Biocentrism' Featured in The Huffington Post - #1 Weblog in the World 2EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator 2
    (Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
    (Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
    (Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
    Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
    ... researchers are developing two inexpensive technologies that may be ... recent outbreak of E. coli in contaminated spinach. , ... , The first method uses a laser to ... about three times faster and one-tenth as expensive as ...
    ... how much detail one remembers of an event depends on ... "package" the memory. , The research may help to explain ... as a car accident, and yet vividly recall all of ... using functional magnetic resonance imaging (fMRI), the scientists were able ...
    ... (UC) environmental health researchers have determined that firefighters are ... cancer than workers in other fields. , Their findings ... the past didn't do a good job in protecting ... the researchers say. , The researchers found, for ...
    Cached Biology News:Researchers develop technologies to devour food pathogens 2Researchers develop technologies to devour food pathogens 3Memories: It's all in the packaging, scientists say 2Firefighters face increased risk for certain cancers 2
    ... For nucleofection of optimized cell lines ... protocol including the nucleofection parameters. Nucleofector ... with the Nucleofector Device., Different cell ... kit. The corresponding efficiencies and viabilities ...
    ... used with its manganese-containing reaction buffer, converts ... of short (1825 bp) interfering RNAs (siRNA) ... 1.3 units (1 l) of ShortCut RNase ... of dsRNA into siRNA suitable for RNA ...
    OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
    ... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
    Biology Products: